Breast Cancer
From the Journals
Combo shows promise in HER2-positive breast cancer with brain mets
Neratinib-capecitabine showed favorable efficacy outcomes, but also high toxicity, in patients with HER2-positive breast cancer and brain...
News
FDA approves another trastuzumab biosimilar for HER2-positive breast cancer, gastric cancer
The Food and Drug Administration has approved Trazimera (trastuzumab-qyyp), a biosimilar of ...
Conference Coverage
Novel immunostimulant combo shows early efficacy
SAN FRANCISCO – A one-two approach to stimulating both innate and adaptive immunity appears to be paying off, suggest early efficacy data from a...
News
FDA approves Tecentriq plus Abraxane in breast cancer
The immunotherapy regimen received accelerated approval for the treatment of PD-L1-positive triple-negative breast cancer in adults.
From the Journals
Novel biomarker could predict resistance to palbociclib
Several biomarkers were linked with the efficacy of palbociclib plus fulvestrant in patients with hormone receptor–positive, metastatic breast...
News
FDA urges caution with robotic devices in cancer surgery
The FDA cites evidence that the use of robotically assisted surgical devices for treatment or prevention of cancers may be associated with...
From the Journals
Anthracycline-free regimen OK in HER2-negative early breast cancer
There were no differences in disease-free or overall survival or distant recurrence-free interval between regimens with or without epirubicin.
From the Journals
FDA Expanded Access benefits heavily pretreated patients, especially children
Although approximately 2% of cancer cases at Memorial Sloan Kettering Cancer Center are pediatric, 34.1% of single-patient uses of investigational...
News
FDA approves subcutaneous trastuzumab for HER2-positive breast cancers
The subcutaneous formulation of trastuzumab can be administered over approximately 2-5 minutes.
From the Journals
Durable responses to ADC sacituzumab in mTNBC
An antibody-drug conjugate induced clinical responses in one third of patients with heavily pretreated metastatic triple-negative breast cancer....
From the Journals
Breast cancer recurrence lower, survival better with dose-intensified regimens
Shorter chemotherapy cycles and sequential dosing were associated with lower recurrence rates and better breast cancer-specific survival.